UCDavis Heart Failure Program

University of California Davis Advanced Cardiac Therapies.

[Gregg Fonarow MD @gcfmd]

Comprehensive Quadruple Therapy for HFrEF

4️⃣💊 ARNI+BB+MRA+SGLT2i

vs historic 3️⃣&2️⃣💊 ACEI+BB+MRA, ACEI+BB

✅ ⬆️⬆️ survival
✅ ⬇️⬇️ 🏨
✅ ⬆️⬆️ health status/QoL
✅ ⬆️⬆️ quality time at home

Remaining ?

Economic value

✅ cost effective

https://t.co/vmcury8KPU

[UCDavis Heart Failure Program @UcdavisP]

Happy holidays from our family to yours.

[UCDavis Heart Failure Program @UcdavisP]

Welcome to the 2022 UCD HF Summit. #heart2heart #UCDavisHFSummit2022

[UCDavis Heart Failure Program @UcdavisP]

Join us for the 2022 UC Davis HF Summit.
https://t.co/9iMrP5Q69F

[Amin Yehya, MD, MS, FACC, FHFSA, ISHLT-F @AminYehyaMD]

Breaking news 🚨: #CardioMems approved for HF patients with NYHA Class II and Class III and/or heart failure hospitalization within 1 year or elevated BNP! #CardioTwitter #MedEd #MedTwitter

[UCDavis Heart Failure Program @UcdavisP]

Shoutout to our EP team! Team work makes the dream work!

[UCDavis Heart Failure Program @UcdavisP]

You know you're in a cardiology clinic when the door looks like ⬇️. Happy Holidays from the UC Davis Heart Failure, MCS , Heart Transplant and Amyloid center Team.

[Michelle Kittleson MD PhD @MKIttlesonMD]

#TipsForNewDocs

Pay attention to available dosages of meds you prescribe frequently.

Ex.: furosemide comes in 20-, 40-. 80-mg tabs. So 60 mg BID is annoying for pts to take- choose 40 BID to 80 BID.

Little details -> less confusion, more adherence = win-win!

#kittlesonrules

[Michelle Kittleson MD PhD @MKIttlesonMD]

#TipsForNewDocs

Consider deleting "congestive heart failure" from your lexicon.

CHF- it's not all congestive

HF - it's too general- is it ischemic cardiomyopathy, familial, chemo-assoc, infiltrative, etc.?

Better terms = better understanding = better care!

#kittlesonrules

[Pam R. Taub, MD❤️💃🏻 @PamTaubMD]

Our study showing ivabradine's benefit for POTS patients is out @JACCJournals. Also has implications for post-COVID 19 POTS (part of long haulers syndrome). Congrats to my co-first author/mentee @AdenaZadourian and the rest of my research team. @Dysautonomia @NIH @UCSDHealth

[UCDavis Heart Failure Program @UcdavisP]

https://t.co/HdhEFv8Hkc
Precision medicine approach based approach to refining heart transplant rejection assessment.

[Gregg Fonarow MD @gcfmd]

Use of SGLT2i together with MRA ⬇️ risk of hyperkalemia
Use of ARNI together with MRA ⬇️ risk of hyperkalemia

Further rationale to start with ARNI+BB+MRA+SGLT2i from day 1 in HFrEF

#GDMTworks

@JavedButler1 @SJGreene_md @mvaduganathan @JJheart_doc @MKIttlesonMD @HFSA @texhern

[Sara C. Martinez MD PhD @saraceciliamtz]

VF with CPR, defib, then normal rhythm, all on TEE. Never seen this
O_o at how the RV takes a major hit.

[Bashaer Gheyath MD FACC 🫀👩🏻‍⚕️ @Bgheyath]

Covid-19 and proposed mechanisms of arrhythmia. Great and relevant read ! #cardiotwitter https://t.co/AaZ8IsGvNc. 2020;142:7–9

[Gregg Fonarow MD @gcfmd]

DKA not seen in HFrEF patients without diabetes treated with SGLT2i

Among those with T2D in DAPA-HF, 3 out of 1075 treated. No DKA reported in EMPEROR-Reduced.

1% increase in genital fungal infections.

Overall AE same or higher with placebo, then SGLT2i.

Benefits >> risks.

[Avraham Z. Cooper, MD 🩺 @AvrahamCooperMD]

1/
Why can furosemide improve dyspnea/pulmonary edema from acute congestive heart failure within minutes of administration?

The answer does not involve diuresis.

#medtwitter #tweetorial

[Gregg Fonarow MD @gcfmd]

Acute myocardial infarction in the young with diabetes mellitus- national inpatient sample study with sex-based difference in outcomes https://t.co/bksiYIrnwS

[Gregg Fonarow MD @gcfmd]

The Four Pillars of Survival Enhancing Medical Therapy for HFrEF

@NMHheartdoc @JavedButler1 @JJheart_doc @MKIttlesonMD @BiykemB @texhern @HFSA #GDMTWorks

Optimal Implementation of SGLT2-i Therapy and Outcome for HF https://t.co/a69mH9aCCi via @JAMACardio part of @JAMANetwork

[Harriette Van Spall, MD MPH 🇨🇦 @hvanspall]

A discussion on #SGLT2i therapy in #HFrEF: an overview of primary outcomes & sensitivity analyses of #DAPAHF, with tips on who & who not to initiate therapy in + what adverse effects to watch out for. Thank you @MIRCIM_course, look forward to presenting the #HF talk in Krakow!

[UCDavis Heart Failure Program @UcdavisP]

#gdmtworks

[Kambiz Ghafourian @KG_heartfailure]

Just saw my patient who is doing well on Carvedilol 50 BID, Sacubitril-Vsartan 49-51 BID, Spiro 25 and Empagliflozin. EF previously 15% now 49%. This made my day!